{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:16:38Z","timestamp":1791432998243,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Friedreich\u2019s ataxia (FA) is a rare genetic disorder caused by silencing of the frataxin gene (\n                      <jats:italic>FXN<\/jats:italic>\n                      )\n                      <jats:italic>,<\/jats:italic>\n                      which leads to multiorgan damage. Nrf2 is a regulator of\n                      <jats:italic>FXN,<\/jats:italic>\n                      which is a modulator of oxidative stress in animals and humans. Omaveloxolone (Omav) is an Nrf2 activator and has been reported to have antioxidative potential in various disease conditions. The present review was conducted to determine the use of Omav, the only FDA-approved treatment for FA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three electronic databases, Cochrane, PubMed and Google Scholar, were searched with terms such as \u2018Omaveloxolone\u2019, \u2018Friedreich ataxia\u2019, \u2018genetic diseases\u2019, \u2018autosomal recessive\u2019, and \u2018rare disorders\u2019 using various advanced search filters. Articles were screened, extracted, and assessed for quality, and a qualitative synthesis of the data was performed. The study protocol was registered in PROSPERO (CRD42024531449).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 201 records were found, with very few published research articles on the topic. Only two randomized clinical trials published in a series of three research articles were included in the current systematic review. Peak load exercise and modified Friedreich\u2019s Ataxia Rating Scale (mFARS) values were considered the major outcome measures for determining the efficacy of 150\u00a0mg Omav capsules\/day in FA. Exploratory outcome measures, such as low-contrast letter visual acuity test, exercise test, T25-FW, 9-HPT, health-related quality of life, and biochemical tests, were also assessed along with adverse events in all the studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although, the quality of the articles demonstrated low bias. However, the short duration, small sample size, and missing data, including the values of different measures of mFARS scores in patients, limit the generalizability of the results. Further studies with longer durations and in severe patients with foot deformities are needed to clearly define the efficacy of Omav in FA and to determine the optimal drug for FA patients in India.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03474-6","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T06:34:45Z","timestamp":1735540485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and efficacy of omaveloxolone v\/s placebo for the treatment of Friedreich's ataxia in patients aged more than 16\u00a0years: a systematic review"],"prefix":"10.1186","volume":"19","author":[{"given":"Ankita","family":"Umrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Pahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabendu Sekhar","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.12.002","author":"F Pilotto","year":"2024","unstructured":"Pilotto F, Chellapandi DM, Puccio H. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends Mol Med. 2024. https:\/\/doi.org\/10.1016\/j.molmed.2023.12.002.","journal-title":"Trends Mol Med"},{"key":"3474_CR2","doi-asserted-by":"publisher","first-page":"1270296","DOI":"10.3389\/fneur.2023.1270296","volume":"14","author":"G Paparella","year":"2023","unstructured":"Paparella G, Strag\u00e0 C, Vavla M, Pesenti N, Merotto V, Martorel GA, et al. Effectiveness of rehabilitation intervention in persons with Friedreich ataxia. Front Neurol. 2023;14:1270296.","journal-title":"Front Neurol"},{"key":"3474_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/10409230600846058","volume":"41","author":"KZ Bencze","year":"2006","unstructured":"Bencze KZ, Kondapalli KC, Cook JD, McMahon S, Mill\u00e1n-Pacheco C, Pastor N, et al. The structure and function of frataxin. Crit Rev Biochem Mol Biol. 2006;41:269\u201391.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"3474_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.29687","volume":"39","author":"E Indelicato","year":"2024","unstructured":"Indelicato E, Reetz K, Maier S, Nachbauer W, Amprosi M, Giunti P, et al. Predictors of survival in Friedreich\u2019s ataxia: a prospective cohort study. Mov Disord. 2024;39:510\u20138.","journal-title":"Mov Disord"},{"key":"3474_CR5","doi-asserted-by":"publisher","first-page":"13291","DOI":"10.1074\/jbc.R900010200","volume":"284","author":"T Nguyen","year":"2009","unstructured":"Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291\u20135.","journal-title":"J Biol Chem"},{"key":"3474_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307:46\u20139.","journal-title":"J Neurol Sci"},{"key":"3474_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","volume":"72","author":"F Pousset","year":"2015","unstructured":"Pousset F, Legrand L, Monin M-L, Ewenczyk C, Charles P, Komajda M, et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol. 2015;72:1334\u201341.","journal-title":"JAMA Neurol"},{"key":"3474_CR8","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1212\/WNL.38.9.1433","volume":"38","author":"M Leone","year":"1988","unstructured":"Leone M, Rocca W, Rosso M, Mantel N, Schoenberg B, Schiffer D. Friedreich\u2019s disease: survival analysis in an Italian population. Neurology. 1988;38:1433.","journal-title":"Neurology"},{"key":"3474_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.47.5.1260","volume":"47","author":"G De Michele","year":"1996","unstructured":"De Michele G, Perrone F, Filla A, Mirante E, Giordano M, De Placido S, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich\u2019s disease: a retrospective study on 119 patients. Neurology. 1996;47:1260\u20134.","journal-title":"Neurology"},{"key":"3474_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","volume":"6","author":"DR Lynch","year":"2019","unstructured":"Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Annal Clin Trans Neurol. 2019;6:15\u201326.","journal-title":"Annal Clin Trans Neurol"},{"key":"3474_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/13543784.2023.2173063","volume":"32","author":"V Profeta","year":"2023","unstructured":"Profeta V, McIntyre K, Wells M, Park C, Lynch DR. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia. Expert Opin Investig Drugs. 2023;32:5\u201316.","journal-title":"Expert Opin Investig Drugs"},{"key":"3474_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3390\/antiox10091466","volume":"10","author":"J-Y Chien","year":"2021","unstructured":"Chien J-Y, Chou Y-Y, Ciou J-W, Liu F-Y, Huang S-P. The effects of two Nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy. Antioxidants. 2021;10:1466.","journal-title":"Antioxidants"},{"key":"3474_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/exd.14564","volume":"31","author":"AJ Cohen-Nowak","year":"2022","unstructured":"Cohen-Nowak AJ, Cohen AJ, Correia ED, Portocarrero CP, South AP, Nikbakht N. Omaveloxolone attenuates squamous cell carcinoma growth and disease severity in an Epidermolysis Bullosa mouse model. Exp Dermatol. 2022;31:1083\u20138.","journal-title":"Exp Dermatol"},{"key":"3474_CR14","doi-asserted-by":"publisher","first-page":"109067","DOI":"10.1016\/j.intimp.2022.109067","volume":"111","author":"W Jian","year":"2022","unstructured":"Jian W, Ma H, Wang D, Yang P, Jiang M, Zhong Y, et al. Omaveloxolone attenuates the sepsis-induced cardiomyopathy via activating the nuclear factor erythroid 2-related factor 2. Int Immunopharmacol. 2022;111:109067.","journal-title":"Int Immunopharmacol"},{"key":"3474_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4564471","author":"L Hu","year":"2022","unstructured":"Hu L, Cao Y, Chen H, Xu L, Yang Q, Zhou H, et al. The novel Nrf2 activator omaveloxolone regulates microglia phenotype and ameliorates secondary brain injury after intracerebral hemorrhage in mice. Oxidat Med Cell Longev. 2022. https:\/\/doi.org\/10.1155\/2022\/4564471.","journal-title":"Oxidat Med Cell Longev"},{"key":"3474_CR16","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1212\/WNL.0000000000008861","volume":"94","author":"KL Madsen","year":"2020","unstructured":"Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, et al. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: Motor trial. Neurology. 2020;94:e687\u201398.","journal-title":"Neurology"},{"key":"3474_CR17","doi-asserted-by":"publisher","first-page":"952950","DOI":"10.3389\/fphar.2022.952950","volume":"13","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Qi G, Lu W, Wang H, Li D, Chen W, et al. Omaveloxolone inhibits IL-1\u03b2-induced chondrocyte apoptosis through the Nrf2\/ARE and NF-\u03baB signalling pathways in vitro and attenuates osteoarthritis in vivo. Front Pharmacol. 2022;13:952950.","journal-title":"Front Pharmacol"},{"key":"3474_CR18","doi-asserted-by":"publisher","first-page":"e22526","DOI":"10.1002\/jbt.22526","volume":"34","author":"SA Reisman","year":"2020","unstructured":"Reisman SA, Ferguson DA, Lee CYI, Proksch JW. Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol. 2020;34:e22526.","journal-title":"J Biochem Mol Toxicol"},{"key":"3474_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1089\/ars.2012.4537","volume":"19","author":"Y Shan","year":"2013","unstructured":"Shan Y, Schoenfeld RA, Hayashi G, Napoli E, Akiyama T, Iodi Carstens M, et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model. Antioxid Redox Signal. 2013;19:1481\u201393.","journal-title":"Antioxid Redox Signal"},{"key":"3474_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fncel.2018.00188","volume":"12","author":"R Abeti","year":"2018","unstructured":"Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models. Front Cell Neurosci. 2018;12:188.","journal-title":"Front Cell Neurosci"},{"key":"3474_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/DDDT.S193889","volume":"13","author":"SA Reisman","year":"2019","unstructured":"Reisman SA, Gahir SS, Lee C-YI, Proksch JW, Sakamoto M, Ward KW. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates. Drug Des Develop Therapy. 2019;13:1259\u201370.","journal-title":"Drug Des Develop Therapy"},{"key":"3474_CR22","unstructured":"Biogen. RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe. ClinicalTrials.gov, 2024."},{"key":"3474_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony S, Corti M, Hoyle JC, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89:212\u201325.","journal-title":"Ann Neurol"},{"key":"3474_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch DR, Chin MP, Boesch S, Delatycki MB, Giunti P, Goldsberry A, et al. Efficacy of omaveloxolone in friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. 2023;38:313\u201320.","journal-title":"Mov Disord"},{"key":"3474_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","volume":"66","author":"D Lynch","year":"2006","unstructured":"Lynch D, Farmer J, Tsou A, Perlman S, Subramony S, Gomez C, et al. Measuring Friedreich ataxia: complementary features of examination and performance measures. Neurology. 2006;66:1711\u20136.","journal-title":"Neurology"},{"key":"3474_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"M Patel","year":"2016","unstructured":"Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Annal Clin Trans Neurol. 2016;3:684\u201394.","journal-title":"Annal Clin Trans Neurol"},{"key":"3474_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acn3.51897","volume":"11","author":"DR Lynch","year":"2024","unstructured":"Lynch DR, Goldsberry A, Rummey C, Farmer J, Boesch S, Delatycki MB, et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Annal Clin Trans Neurol. 2024;11:4\u201316.","journal-title":"Annal Clin Trans Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03474-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:03:48Z","timestamp":1735542228000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03474-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03474-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"5 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"495"}}